• Search

Search in Site

Industry news and analysis across pharma and medical devices PharmaDeviceNews.com

  • Home
  • Pharma & Biotech
  • Medical Devices & Diagnostics
  • Features & Analysis
  • Privacy Policy
  • About PharmaDeviceNews
  • Editorial Policy
  • Disclaimer
  • Contact Us
Home»Posts tagged with»crinecerfont

Neurocrine’s CAHtalyst pediatric data sharpens the case for CRENESSITY durability

By Pallavi Madhiraju on May 3, 2026   Pharma & Biotech  

Neurocrine’s CAHtalyst pediatric data sharpens the case for CRENESSITY durability

Steroid reduction is the real test in pediatric CAH. Neurocrine’s CRENESSITY data now faces the durability, access and adoption question.

Recent Posts

  • Why Sensus Healthcare’s SkinCure resolution matters for superficial radiotherapy growth
  • Why Encompass Health is betting on a fast-growing Texas suburb before rivals crowd in
  • What Saban Community Clinic’s Crenshaw project reveals about urban healthcare deserts
  • Cryo-Cell avoided a delisting scare for now, but investors still face a 2027 countdown
  • Ensoma’s EN-374 safety data open a new test for in vivo HSC engineering
  • Why bioAffinity’s CyPath Lung growth still leaves investors facing a hard cash question
  • Can Kanvas Biosciences turn microbiome replacement into a maternal health intervention?
  • Could Actio’s KCNT1 epilepsy drug become an ultra-rare disease test case for the FDA?
  • Lumenis strengthens FoLix, ULTRApulse Alpha and Stellar M22 case with ASLMS data
  • How Zifo’s AI authoring platform could reshape clinical and CMC documentation
  • INOVIO’s ASCO and ASGCT updates may sharpen scrutiny of its DNA medicine strategy
  • Pharma has a Hispanic engagement problem. Relevant+ thinks Healthy Vibras can fix it
    • About PharmaDeviceNews
    • Contact Us
    • Disclaimer
    • Editorial Policy
    • Privacy Policy
© 2026, ↑ PharmaDeviceNews
Log in - Powered by WordPress - Gabfire Themes